pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ELI LILLY CO · news · pharmadog
← back to ELI LILLY CO
News mentioning ELI LILLY CO
630
stories
Aug 5, 26
Lilly climbs, Novo falls as obesity drug battle intensifies
biopharma dive
Aug 5, 26
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
biospace
Aug 5, 26
STAT+: Moderna launches early trial of Ebola mRNA vaccine
stat
Aug 5, 26
Novo CEO sees innovation as a matter of survival amid pipeline setbacks
biospace
Aug 5, 26
Lilly once again beats expectations as tirzepatide accounts for 64% of revenue
endpoints
Aug 5, 26
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
Aug 5, 26
‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
fiercebiotech
Aug 5, 26
Lilly drops another gene therapy trial from $1B Prevail buyout
fiercebiotech
Aug 5, 26
STAT+: Senate inquiry suggests Trump administration softened kratom and tobacco policies in quid pro quo
stat
Aug 5, 26
STAT+: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis finds
stat
Aug 5, 26
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
Aug 5, 26
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
fiercebiotech
Aug 4, 26
Novo dips 6% on Wegovy pill stumble despite Q2 earnings beat
biospace
Aug 4, 26
STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans
stat
Aug 4, 26
STAT+: Three biotechs with three news updates
stat
Aug 4, 26
Novo vs. Lilly: Q2's cardiometabolic grudge match
endpoints
Aug 4, 26
STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more
stat
Aug 4, 26
Trans federal employees sue over revoked health coverage
stat
Aug 4, 26
STAT+: As Trump administration pushes court-ordered mental health care, a new report raises questions
stat
Aug 3, 26
STAT+: Eli Lilly to allow more patients to apply for special access to unapproved obesity drug
stat
Aug 3, 26
Curium strikes up to $8B deal for radiopharma rival Lantheus
fiercebiotech
Aug 3, 26
STAT+: Is there a pharma mega-merger in the making?
stat
Aug 2, 26
STAT+: Michigan Supreme Court ruling allows probe into Lilly insulin pricing
stat
Jul 31, 26
Trump administration tries again to institute rebates in 340B
biopharma dive
Jul 31, 26
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
biospace
Jul 31, 26
Resilience and Lilly invest $750M to boost Cincinnati drug production
biopharma dive
Jul 31, 26
Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
biospace
Jul 31, 26
Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
fiercebiotech
Jul 30, 26
Capricor’s data clash and a fugitive in the C-suite
stat
Jul 30, 26
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
← prev
page 13 of 21
next →
